Species |
SARS-CoV-2 |
Protein Construction |
N protein [Ser2-Ala419 (G204R, R203K)] Accession # P0DTC9 |
Poly-His |
N-term |
C-term |
|
Purity |
≥ 90% as analyzed by SDS-PAGE |
Biological Activity |
SARS-CoV-2 Nucleocapsid protein (G204R, R203K), His Tag (Cat. No. Z03731) can bind with SARS-CoV-2 Nucleocapsid Antibody, Human Chimeric (Cat. No. ) in functional ELISA assay. |
Expression System |
E. coli |
Theoretical Molecular Weight |
46 kDa |
Apparent Molecular Weight |
~55 kDa, on SDS-PAGE under reducing conditions. |
Formulation |
Supplied as a solution in PBS pH 7.4 containing 10% glycerol. |
Concentration |
Please refer to the COA for the specific lot. |
Storage & Stability |
Upon receiving, this product remains stable for up to 6 months at -20 °C or below. Avoid repeated freeze-thaw cycles. |
![SARS-CoV-2 Nucleocapsid Protein (G204R, R203K), His Tag SARS-CoV-2 Nucleocapsid Protein (G204R, R203K), His Tag](/product/documents/down?doc_name=Z03731_ELISA.jpg&file=scm_files/productFile_notes/2021/12/21/d365f90d-6f25-45f3-b43e-fa26bc38b1b8.jpg)
Immobilized SARS-CoV-2 Nucleocapsid Antibody, Human Chimeric (Cat. No. ) at 2 μg/ml can bind SARS-CoV-2 Nucleocapsid protein (G204R, R203K), His Tag (Cat.No. Z03731) with a serial dilution.
THE™ His Tag Antibody [HRP], mAb, Mouse (Cat.No. ) is used as a secondary antibody (0.2 μg/ml).
![SARS-CoV-2 Nucleocapsid Protein (G204R, R203K), His Tag SARS-CoV-2 Nucleocapsid Protein (G204R, R203K), His Tag](/product/documents/down?doc_name=Z03731_SDS.jpg&file=scm_files/productFile_notes/2021/12/21/57909ca0-ac88-4dba-9045-147464ef79f0.jpg)
Lane 1: 1 μg of SARS-CoV-2 Nucleocapsid protein (G204R, R203K), His Tag (Cat.No. Z03731) (NR)
Lane 2: 1 μg of SARS-CoV-2 Nucleocapsid protein (G204R, R203K), His Tag (Cat.No. Z03731) (R)
≥ 90% as analyzed by SDS-PAGE
Target Background |
SARS-CoV-2 (Severe Acute Respiratory
Syndrome Coronavirus 2) also known as 2019-nCoV (2019 Novel Coronavirus) is a virus that causes illnesses ranging from the common cold to severe diseases. Recently, the new B.1.1.529 variant was confirmed in South Africa and preliminary evidence suggests an increased risk of reinfection with this variant. The B.1.1.529 variant was first reported to WHO on 24 November 2021 and WHO has designated this variant as a VOC (Variant of Concern), named Omicron. There are more than 30 mutations in the spike protein. |
Synonyms |
B.1.1.529; Omicron variant |
References |
1. .
2. . |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.